Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a

Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

G04CA02 TAMSULOSINUM CAPS. ELIB. MODIF. 0,4 mg

TAMSOL 0,4 mg 0,4 mg GEDEON RICHTER ROMANIA

TAMSULOSIN ACTAVIS 0,4 mg ACTAVIS GROUP HF.

G04CA02 TAMSULOSINUM CAPS. ELIB. MODIF. 0.4 mg

FOKUSIN 0.4 mg ZENTIVA AS

G04CA02 TAMSULOSINUM CAPS. ELIB. PREL. 0.4 mg

CONTIFLO MR 0.4 mg RANBAXY UK LTD.

TANYZ 0.4 mg KRKA D.D. NOVO MESTO
G04CA02 TAMSULOSINUM COMPR. FILM. ELIB. 0.4 mg

PREL.

OMNIC TOCAS(R) 0,4 0.4 mg ASTELLAS PHARMA EUROPE

B.V.
______________________________________________________________________________

| 279 |G04CB01| FINASTERIDUM* | |

|_______|_______|____________________________________________|_________________|

Prescriere limitată: Tratamentul hiperplaziei benigne de prostată.

Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

G04CB01 FINASTERIDUM COMPR. FILM. 5 mg

MOSTRAFIN 5 mg PLIVA LJUBLIJANA D.O.O.

PROSCAR 5 mg 5 mg MERCK SHARP & DOHME

ROMANIA S.R.L.

TAREDOX 5 mg 5 mg DR. REDDY'S LABORATORIES

G04CB01 FINASTERIDUM COMPR. FILM. 5 mg

MOSTRAFIN 5 mg PLIVA LJUBLIJANA D.O.O.

PROSCAR 5 mg 5 mg MERCK SHARP & DOHME

ROMANIA S.R.L.

TAREDOX 5 mg 5 mg DR. REDDY'S LABORATORIES
G04CB01 FINASTERIDUM COMPR. FILM. 5 mg

FINASTERID SANDOZ 5 mg 5 mg HEXAL AG

______________________________________________________________________________

| 280 |G04CB02| DUTASTERIDUM* | |

|_______|_______|____________________________________________|_________________|
Prescriere limitată: Tratamentul hiperplaziei benigne de prostată.

Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

G04CB02 DUTASTERIDUM CAPS. MOI 0.5 mg

AVODART(R) 0.5 mg GLAXO GROUP LTD.
______________________________________________________________________________

| 281 |H01AA02| TETRACOSACTIDUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H01AA02 TETRACOSACTIDUM SUSP. INJ. 1 mg/ml

SYNACHTEN DEPOT 1 mg/ml NOVARTIS PHARMA GMBH
______________________________________________________________________________

| 282 |H01AC01| SOMATROPINUM***# | Protocol: H009E |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H01AC01 SOMATROPINUM SOL. INJ. 10 mg/1.5 ml

NORDITROPIN 10 mg/1.5 ml NOVO NORD ISK A/S

SIMPLEX x 10 mg/1,5 ml

H01AC01 SOMATROPINUM SOL. INJ. 10 mg/2 ml

NUTROPINAq 10 mg/2 ml 10 mg/2 ml IPSEN LIMITED

H01AC01 SOMATROPINUM SOL. INJ. 3,3 mg/ml

OMNITROPE 3,3 mg/ml 3,3 mg/ml SANDOZ GMBH

H01AC01 SOMATROPINUM LIOF. + SOLV. PT. SOL. 4 mg (12 ui)

INJ.

ZOMACTON 4 mg (12 ui) FERING GMBH
H01AC01 SOMATROPINUM PULB. + SOLV. PT. SOL. 5.3 mg/ml (16 ui)

INJ.

GENOTROPIN(R) 16 ui (5,3 mg) 5.3 mg/ml (16 ui) PFIZER EUROPE MA EEIG
H01AC01 SOMATROPINUM SOL. INJ. 5 mg/1.5 ml

NORDITROPIN 5 mg/1.5 ml NOVO NORDISK A/S

SIMPLEX x 5 mg/1,5 ml
______________________________________________________________________________

| 283 |H01CC01| GANIRELIXUM***# | Protocol: G004N |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H01CC01 GANIRELIXUM SOL. INJ. 0.25 mg/0.5 ml

ORGALUTRAN 0.25 mg/0.5 ml 0.25 mg/0.5 ml N.V. ORGANON
______________________________________________________________________________

| 284 |H01CC02| CETRORELIXUM***# | Protocol: H004E |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H01CC02 CETRORELIXUM LIOF. + SOLV. PT. SOL. 0.25 mg

INJ.

CETROTIDE 0,25 mg 0.25 mg SERONO EUROPE LTD.

H01CC02 CETRORELIXUM LIOF. + SOLV. PT. SOL. 3 mg

INJ.

CETROTIDE 3 mg 3 mg SERONO EUROPE LTD.
______________________________________________________________________________

| 285 |H02AA02| FLUDROCORTISONUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H02AA02 FLUDROCORTISONUM COMPR. 0.1 mg

ASTONIN H 0.1 mg MERCK KGAA
______________________________________________________________________________

| 286 |H02AB01| BETAMETHASONUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H02AB01 BETAMETHASONUM SUSP. INJ. I.M. 7 mg/ml

DIPROPHOS(R) 7 mg/ml SCHERING PLOUGH EUROPE
______________________________________________________________________________

| 287 |H02AB06| PREDNISOLONUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H02AB06 PREDNISOLONUM LIOF. + SOLV. PT. SOL. 250 mg

INJ.

SOLU-DECORTIN H 250 250 mg MERCK KGAA

H02AB06 PREDNISOLONUM LIOF. + SOLV. PT. SOL. 50 mg

INJ.

SOLU-DECORTIN H 50 50 mg MERCK KGAA
______________________________________________________________________________

| 288 |H03BB02| THIAMAZOLUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H03BB02 THIAMAZOLUM COMPR. FILM. 10 mg

THYROZOL(R) 10 mg 10 mg MERCK KGAA
H03BB02 THIAMAZOLUM COMPR. FILM. 20 mg

THYROZOL(R) 20 mg 20 mg MERCK KGAA

H03BB02 THIAMAZOLUM COMPR. FILM. 5 mg

THYROZOL(R) 5 mg 5 mg MERCK KGAA

______________________________________________________________________________

| 289 |H05BA01| CALCITONINUM (SOMON) | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H05BA01 CALCITONINUM (SOMON) SOL. INJ. 100 UI

TONOCALCIN 100 UI 100 UI ALFA WASSERMANN SPA
H05BA01 CALCITONINUM (SOMON) SPRAY NAZ., SOL. 100 ui/doza

NYLEX 100 Ul/doza 100 UI/doza PHARMACEUTICAL IND. PROEL

EPAM. G. CORONIS SA
H05BA01 CALCITONINUM (SOMON) SOL. INJ. 100 UI/ml

NYLEX(R) 100 UI/ml PROEL E.P. CORONIS SA

H05BA01 CALCITONINUM (SOMON) SPRAY NAZAL-SOL. 200 UI/doza

MIACALCIC(R) NASAL 200 200 ui/doza NOVARTIS PHARMA GMBH

NYLEX(R) 200 UI/doza PROEL E.P. CORONIS SA
H05BA01 CALCITONINUM (SOMON) SOL. INJ. 50 ui/ml

MIACALCIC(R) 50 ui/ml NOVARTIS PHARMA GMBH

______________________________________________________________________________

| 290 |J01CR01| AMPICILLINUM + SULBACTAM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01CR01 AMPICILLINUM + PULB. PT. SOL. INJ. 1 g + 500 mg

SULBACTAM

AMPIPLUS(R) 1,5 g 1 g + 500 mg ANTIBIOTICE SA

______________________________________________________________________________

| 291 |J01CR04| SULTAMICILLINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01CR04 SULTAMICILLINUM PULB. PT. SUSP. ORALĂ 250 mg/5 ml

UNASYN 250 mg/5 ml PFIZER EUROPE MA EEIG
J01CR04 SULTAMICILLINUM COMPR. FILM. 375 mg

UNASYN 375 mg PFIZER EUROPE MA EEIG

______________________________________________________________________________

| 292 |J01DC10| CEFPROZILUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01DC10 CEFPROZILUM PULB. PT. SUSP. ORALĂ 125 mg/5 ml

CEFZIL 125 mg/5 ml 125 mg/5 ml BRISTOL-MYERS SQUIBB KFT.
J01DC10 CEFPROZILUM COMPR. FILM. 250 mg

CEFZIL 250 mg 250 mg BRISTOL-MYERS SQUIBB KFT.

J01DC10 CEFPROZILUM PULB. PT. SUSP. ORALĂ 250 mg/5 ml

CEFZIL 250 mg/5 ml 250 mg/5 ml BRISTOL-MYERS SQUIBB KFT.

J01DC10 CEFPROZILUM COMPR. FILM. 500 mg

CEFZIL 500 mg 500 mg BRISTOL-MYERS SQUIBB KFT.

______________________________________________________________________________

| 293 |J01DD14| CEFTIBUTENUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01DD14 CEFTIBUTENUM PULB. PT. SUSP. ORALĂ 36 mg/ml

CEDAX 36 mg/ml SCHERING PLOUGH EUROPE
J01DD14 CEFTIBUTENUM CAPS. 400 mg

CEDAX 400 mg SCHERING PLOUGH EUROPE

______________________________________________________________________________

| 294 |J01FA02| SPIRAMYCINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01FA02 SPIRAMYCINUM COMPR. FILM. 1.5 M ui

ROVAMYCINE(R) 1,5 Mil. UI 1.5 M ui LAB. AVENTIS
J01FA02 SPIRAMYCINUM COMPR. FILM. 3 M ui

ROVAMYCINE(R) 3 Mil. UI 3 M ui LAB. AVENTIS

________________________________________________________________________________
______________________________________________________________________________

| 295 |J01FA10| AZITHROMYCINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01FA10 AZITHROMYCINUM PULB. PT. SUSP. ORALĂ 100 mg/5 ml

AZITROMICINA 100 mg/5 ml SANDOZ SRL

SANDOZ 100 mg/5 ml

J01FA10 AZITHROMYCINUM COMPR. FILM. 125 mg

SUMAMED 125 mg 125 mg PLIVA LJUBLJANA D.O.O.

J01FA10 AZITHROMYCINUM PULB. PT. SUSP. ORALĂ 200 mg/5 ml

AZITROMICINA 200 mg/5 ml SANDOZ SRL

SANDOZ 200 mg/5 ml
J01FA10 AZITHROMYCINUM PULB. + SOLV. SUSP. 200 mg/5 ml

ORALĂ

AZITROX 200 mg/5 ml 200 mg/5 ml ECZACIBASI PHARMACEUTICALS

S.R.L.
J01FA10 AZITHROMYCINUM PULB. PT. SUSP. ORALĂ 200 mg/5 ml

SUMAMED FORTE 200 mg/5 ml PLIVA LJUBLIJANA D.O.O.
J01FA10 AZITHROMYCINUM CAPS. 250 mg

AZATRIL 250 mg 250 mg BALKANPHARMA RAZGRAD AD

J01FA10 AZITHROMYCINUM COMPR. FILM. 250 mg

AZITROMICINA SANDOZ 250 mg 250 mg SANDOZ S.R.L.

COMPRIMATE FILMATE

AZITROX(R) 250 250 mg ZENTIVA AS

J01FA10 AZITHROMYCINUM COMPR. FILM. 500 mg

AZITROMICINA SANDOZ 500 mg 500 mg SANDOZ S.R.L.

COMPRIMATE FILMATE

AZITROX(R) 500 500 mg ZENTIVA AS

AZRO(R) 500 mg 500 mg ECZACIBASI PHARMACEUTICALS

S.R.L.

SUMAMED 500 mg 500 mg PLIVA LJUBLJANA D.O.O.

ZITROCIN 500 mg 500 mg OZONE LABORATORIES LTD.

J01FA10 AZITHROMYCINUM GRAN. ELIB. PREL. PT. 2 g

SUSP. ORALĂ

ZMAX 2 g 2 g PFIZER EUROPE MA EEIG

________________________________________________________________________________

______________________________________________________________________________

| 296 |J01FF01| CLINDAMYCINUM | |

|_______|_______|____________________________________________|_________________|
Prescriere limitată: Infecţii cu coci Gram pozitivi care nu pot fi tratate

eficient cu peniciline.

Infecţii severe cu germeni anaerobi.

Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01FF01 CLINDAMYCINUM CAPS. 150 mg

DALACIN C 150 mg 150 mg PFIZER EUROPE MA EEIG
J01FF01 CLINDAMYCINUM CAPS. 300 mg

DALACIN C 300 mg 300 mg PFIZER EUROPE MA EEIG

________________________________________________________________________________
______________________________________________________________________________

| 297 |J01MA12| LEVOFLOXACINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01MA12 LEVOFLOXACINUM COMPR. FILM. 500 mg

TAVANIC(R) 500 mg AVENTIS PHARMA DEUTSCHLAND

GMBH

________________________________________________________________________________
______________________________________________________________________________

| 298 |J01MA14| MOXIFLOXACINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01MA14 MOXIFLOXACINUM COMPR. FILM. 400 mg

AVELOX(R) 400 mg 400 mg BAYER HEALTHCARE AG

________________________________________________________________________________

______________________________________________________________________________

| 299 |J02AC02| ITRACONAZOLUM* | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J02AC02 ITRACONAZOLUM CAPS. 100 mg

ITRACONAZOL 100 mg 100 mg TERAPIA S.A.

OMICRAL 100 mg 100 mg MEDICO UNO PHARMACEUTICAL

S.R.L

ORUNGAL 100 mg JANSSEN PHARMACEUTICA NV

________________________________________________________________________________
______________________________________________________________________________

| 300 |J05AB11| VALACYCLOVIRUM* | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J05AB11 VALACYCLOVIRUM COMPR. FILM. 500 mg

VALTREX 500 mg 500 mg THE WELLCOME FOUNDATION

LTD
Prescriere limitată: Tratamentul pacienţilor cu herpes zoster în decurs de 72 de ore de la debutul rash-ului

Prescriere limitată: Herpes zoster oftalmic.

Prescriere limitată: Herpes genital iniţial moderat/sever.

Prescriere limitată: Tratamentul episodic sau supresiv al herpesului genital recurent (forme moderate/severe).
________________________________________________________________________________
______________________________________________________________________________

| 301 |J05ABN1| BRIVUDINUM*# | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________
Prescriere limitată: Tratamentul pacienţilor cu herpes zoster în decurs de 72 de ore de la debutul rash-ului.
J05ABN1 BRIVUDINUM COMPR. 125 mg

BRIVAL(R) 125 mg BERLIN CHEMIE AG MENARINI

GROUP

________________________________________________________________________________

______________________________________________________________________________

| 302 |L01AA01| CYCLOPHOSPHAMIDUM* | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L01AA01 CYCLOPHOSPHAMIDUM DRAJ. 50 mg

ENDOXAN(R) 50 mg 50 mg BAXTER ONCOLOGY GMBH

________________________________________________________________________________

______________________________________________________________________________

| 305 |L02AE04| TRIPTORELINUM***# | Protocol: L013E |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________
Prescriere limitată: Tratamentul de scurtă durată (până la 6 luni) al

endometriozei confirmate histologic.

Tratamentul pubertăţii precoce.

Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
L02AE04 TRIPTORELINUM LIOF. + SOLV. PT. 0.1 mg

SOL. INJ.

DIPHERELINE 0,1 mg 0.1 mg BEAUFOUR IPSEN PHARMA
L02AE04 TRIPTORELINUM LIOF. + SOLV. PT. SUSP. 11.25 mg

INJ. I.M. ELIB. PREL

DIPHERELINE(R) 11,25 mg 11.25 mg BEAUFOUR IPSEN PHARMA
L02AE04 TRIPTORELINUM LIOF. +SOLV. PT. SUSP. 3.75 mg

INJ. I.M. ELIB. PREL.

DIPHERELINE(R) 3,75 mg 3.75 mg BEAUFOUR IPSEN PHARMA

________________________________________________________________________________

______________________________________________________________________________

| 306 |L04AX01| AZATHIOPRINUM* | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L04AX01 AZATHIOPRINUM COMPR. FILM. 50 mg

IMURAN(R) 50 mg THE WELLCOME FOUNDATION

LTD.

________________________________________________________________________________
______________________________________________________________________________

| 307 |M01AC01| PIROXICAMUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________
A se administra cu precauţie la pacienţii cu istoric de factori de risc sau afecţiuni gastrointestinale.